Abstract
Attention-deficit hyperactivity disorder (ADHD) is characterized by symptoms of inattention and/or hyperactivity and impulsivity. It is frequently present in substance use disorder (SUD) patients; estimates of the prevalence of ADHD vary between 14 % and 23 % in SUD populations. The high comorbidity is partly based on communal underlying neurobiological characteristics such as a shared genetic background of the two disorders. Neuropsychological correlates of both disorders include a dysfunction of the motivational/reward system and impulsivity. In general, patients with this type of comorbidity represent a more severe subgroup of SUD patients with more additional comorbidity and a more disadvantageous prognosis and higher treatment drop-out than SUD patients without ADHD. It is important to detect and treat ADHD in SUD patients, and substance use disorder treatment centers can play an important role in this by screening for ADHD. Treatment options may include medication, although convincing evidence of effect in SUD populations is yet lacking, and cognitive behavioral therapy. As problems of SUD and ADHD can be intertwined, it is appropriate to start ADHD treatment during SUD treatment, ideally after initial stabilization of substance use. As this patient group is characterized by high complexity, further research and development of integrated treatment programs are warranted.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arcos-Burgos M, Velez JI, Solomon BD et al (2012) A common genetic network underlies substance use disorders and disruptive or externalizing disorders. Hum Genet 131:917–929
Arias AJ, Gelernter J, Chan G et al (2008) Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav 33:1199–1207
Barkley RA (1997) Attention-deficit/hyperactivity disorder, self-regulation, and time: toward a more comprehensive theory. J Dev Behav Pediatr 18:271–279
Barkley RA, Brown TE (2008) Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. CNS Spectr 13:977–984
Biederman J, Faraone SV, Spencer TJ et al (2006) Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry 67:524–540
Bush G, Frazier JA, Rauch SL et al (1999) Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol Psychiatry 45:1542–1552
Castellanos FX, Lee PP, Sharp W et al (2002) Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 288:1740–1748
Castellanos FX, Proal E (2012) Large-scale brain systems in ADHD: beyond the prefrontal-striatal model. Trends Cogn Sci 16:17–26
Castells X, Ramos-Quiroga JA, Rigau D et al (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–169
Charach A, Yeung E, Climans T et al (2011) Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry 50:9–21
Cortese S, Castellanos FX (2012) Neuroimaging of attention-deficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr Psychiatry Rep 14:568–578
Crunelle CL, van den Brink W, Veltman DJ et al (2013) Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence. Eur Neuropsychopharmacol 23:1714–1723
Durston S, van Belle J, de Zeeuw P (2011) Differentiating frontostriatal and fronto-cerebellar circuits in attention-deficit/hyperactivity disorder. Biol Psychiatry 69:1178–1184
Epstein JE, Johnson DE, Conners CK (2001) Conners’ adult ADHD diagnostic interview for DSM-IV (CAADID). Technical Manual. MHS, Toronto
Ercan ES, Coskunol H, Varan A et al (2003) Childhood attention deficit/hyperactivity disorder and alcohol dependence: a 1-year follow-up. Alcohol Alcohol 38:352–356
Faraone SV, Biederman J, Mick E (2006) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36:159–165
Faraone SV, Perlis RH, Doyle AE et al (2005) Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1313–1323
Faraone SV, Sergeant J, Gillberg C (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104–113
Franke B, Faraone SV, Asherson P et al (2012) The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 17:960–987
Kessler RC, Adler L, Barkley R et al (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716–723
Konstenius M, Jayaram-Lindstrom N, Beck O et al (2010) Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 108:130–133
Konstenius M, Jayaram-Lindström N, Guterstam J et al (2014) Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction 109:440–449
Kooij SJ, Bejerot S, Blackwell A et al (2010) European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 10:67
Kooij JJS, Francken MH (2010) DIVA. DIVA foundation, Den Haag
Levin FR, Evans SM, Brooks DJ et al (2007) Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87:20–29
Mészáros A, Czobor P, Bálint S et al (2009) Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12:1137–1147
Nigg J (2005) Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: The state of the field and salient challenges for the coming decade. Biol Psychiatry 57:1424–1435
Pennington BF, Ozonoff S (1996) Executive functions and developmental psychopathology. J Child Psychol Psychiatry 37:51–87
Plomp AS, Bergen AA, Florijn RJ et al (2009) Pseudoxanthoma elasticum: Wide phenotypic variation in homozygotes and no signs in heterozygotes for the c.3775delT mutation in ABCC6. Genet Med 11:852–858
Proal E, Reiss PT, Klein RG et al (2011) Brain gray matter deficits at 33-year follow-up in adults with attention-deficit/hyperactivity disorder established in childhood. Arch Gen Psychiatry 68:1122–1134
Safren SA, Perlman CA, Sprich S et al (2005) Mastering your adult ADHD: a cognitive-behavioral therapy approach. University Press, New York
Safren SA, Sprich S, Mimiaga MJ et al (2010) Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 304:875–880
Shaw M, Hodgkins P, Caci H et al (2012) A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med 10:99
Simon V, Czobor P, Balint S et al (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204–211
Sonuga-Barke EJ (2003) The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 27:593–604
Swanson J, Baler RD, Volkow ND (2011) Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology 36:207–226
van de Glind G, van den Brink W, Koeter MW et al (2013) Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug Alcohol Depend 132:587–596
van de Glind G, Konstenius M, Koeter MW et al (2014) Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients; Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug Alcohol Depend 134:158–166
van Emmerik-van Oortmerssen K, van de Glind G, Koeter MWJ et al (2014) Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder; results of the IASP study. Addiction 109:262–272
van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W et al (2012) Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend 122:11–19
van Emmerik-van Oortmerssen K, Vedel E, Koeter MW et al (2013) Investigating the efficacy of integrated cognitive behavioral therapy for adult treatment seeking substance use disorder patients with comorbid ADHD: Study protocol of a randomized controlled trial. BMC Psychiatry 13:132
Volkow ND, Wang GJ, Fowler JS et al (2012) Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 52:321–336
Wilens TE, Adler LA, Weiss MD et al (2008) Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 96:145–154
Wilens TE, Biederman J, Faraone SV et al (2009) Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry 70:1557–1562
Wilens T, Faraone SV, Biederman J (2004) Attention-deficit/hyperactivity disorder in adults. JAMA 292:619–623
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
van Emmerik-van Oortmerssen, K., Konstenius, M., Schoevers, R.A. (2015). ADHD and Addiction. In: Dom, G., Moggi, F. (eds) Co-occurring Addictive and Psychiatric Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45375-5_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-45375-5_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45374-8
Online ISBN: 978-3-642-45375-5
eBook Packages: MedicineMedicine (R0)